MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Results 1 - 20 of 159 : 1 2 3 4 5 6 7 8 Next »

Recs

0
Member Avatar deno075 (26.87) Submitted: 4/10/2014 7:40:45 PM : Outperform Start Price: $6.84 MNKD Score: -10.94

Almost there with new drug.

Recs

0
Member Avatar DrGarnicus (21.75) Submitted: 4/10/2014 3:37:47 PM : Outperform Start Price: $6.90 MNKD Score: -10.91

July 15th

Recs

0
Member Avatar Piggybank99 (58.10) Submitted: 4/4/2014 6:48:14 PM : Outperform Start Price: $6.12 MNKD Score: +1.86

This company recently got its inhalable insulin approved by the FDA, and once it gets on the market, prices will go through the roof.

Recs

0
Member Avatar kickbishopbrenna (35.72) Submitted: 4/4/2014 10:42:57 AM : Outperform Start Price: $6.87 MNKD Score: -7.58

no insulin injections..wow, its a "pot-shot" but with FDA approval discussions due to start, its worth a punt, especially as the select committee have recommended it.

Recs

0
Member Avatar OklaBoston (68.16) Submitted: 4/2/2014 4:44:42 PM : Underperform Start Price: $7.19 MNKD Score: +11.60

4 ranking from http://www.zacks.com the reason for my red thumb.

Up-trended insider ownership the reason I don't to change the time frame and will probably go the other way eventually.

Recs

5
Member Avatar zzlangerhans (99.73) Submitted: 4/1/2014 7:29:00 PM : Outperform Start Price: $4.01 MNKD Score: +56.26

This would be a perfect time for me to blast out to everyone that I knew, absolutely knew that Afrezza would get a positive Ad Comm vote and by the way I had ten grand on the April 5 calls. Of course, binary catalysts don't really work for me that way. On the rare occasions I call them correctly, I've either recently closed my position or never had one. If I've got skin in the game, look out below.

I green thumbed Mannkind impulsively near the close on Monday after I saw them beaten down to a point where the risk/reward balance had shifted. Most of the smart people I follow were very negative about Afrezza's clinical data for a variety of reasons, and I wasn't about to mess up my recent moderately successful trade with a dumb gamble. On the other hand, the set up reminded me of the Ad Comms for Chelsea Therapeutics: lots of negative commentary, a beaten up stock, but little evidence of safety concerns. Ad Comms are often surprisingly lenient, ignoring trial design flaws and data anomalies that make the biopharma Twitterati foam at the mouth.

So here we are after hours with a hugely positive panel vote, a double in the share price, and lots of question marks for the future. I don't think the share price will sag too much ahead of the PDUFA in two weeks, unless it gets postponed. If that does occur and the share price drops below 7 for even a second I would get in because there's a virtual certainty Afrezza will be approved this time around and will revist 8 or higher. Naturally, I wouldn't hang around and wait to see how sales affect Mannkind's nightmarish balance sheet.

Recs

0
Member Avatar seti03 (< 20) Submitted: 3/28/2014 4:22:43 PM : Outperform Start Price: $4.44 MNKD Score: +40.91


hmmm, works quicker and no more sticking yourself like a pin cushion. What's not to approve???

Recs

2
Member Avatar usubanas (99.53) Submitted: 3/28/2014 1:55:16 PM : Underperform Start Price: $5.02 MNKD Score: -24.10

predict FDA panel will vote negatively next week.

Recs

0
Member Avatar pavlos1971 (99.69) Submitted: 3/28/2014 8:05:39 AM : Underperform Start Price: $5.64 MNKD Score: -10.12

tied to an imbalance of lung cancers.. that won't go well.

Recs

1
Member Avatar MOEHESTON (< 20) Submitted: 3/22/2014 9:41:19 AM : Outperform Start Price: $5.90 MNKD Score: +6.16

Unless all are not being told something. All elements have been answered. The ADCOM article (yet to surface) will probably not paint a favorable picture creating one more dip. Then FDA response (April 15th).

Recs

2
Member Avatar palm91 (25.19) Submitted: 3/3/2014 2:42:13 PM : Outperform Start Price: $6.08 MNKD Score: +2.12

best bet in biomeds, look for 25billion MC

Recs

0
Member Avatar jdowning22 (41.58) Submitted: 1/18/2014 8:06:56 PM : Outperform Start Price: $5.56 MNKD Score: +10.71

New drug coming soon... Hopefully

Recs

0
Member Avatar dswallen (33.14) Submitted: 1/15/2014 5:44:35 PM : Outperform Start Price: $6.00 MNKD Score: +3.02

Thinking the drug gets approved and we get a big pop. After that, time to sell sell sell.

Recs

0
Member Avatar babatariq (< 20) Submitted: 1/10/2014 12:29:17 AM : Outperform Start Price: $6.69 MNKD Score: -7.90

novel treatment for dibetes,in multibillion industry.

Recs

1
Member Avatar optionsmaster (40.96) Submitted: 12/20/2013 10:50:00 AM : Outperform Start Price: $4.98 MNKD Score: +22.79

New product launch of diabetes drug

Recs

1
Member Avatar SqwiiTrader (37.30) Submitted: 12/5/2013 8:32:53 PM : Outperform Start Price: $4.98 MNKD Score: +22.34

big IHS monthly

Recs

0
Member Avatar dunloggin (76.86) Submitted: 11/7/2013 5:57:34 PM : Outperform Start Price: $4.69 MNKD Score: +26.67

Increased cash position....

Recs

0
Member Avatar Rajhi (60.41) Submitted: 10/30/2013 5:24:23 PM : Outperform Start Price: $4.97 MNKD Score: +19.94

Y

Recs

0
Member Avatar omkarnk (< 20) Submitted: 8/23/2013 12:21:00 PM : Outperform Start Price: $5.51 MNKD Score: +1.33

There is a saying called "Practice makes a man perfect". Mannkind has been working on this drug for such a long time that it would have removed any major issues with related to it. Also, given a choice of injecting yourself multiple times a day or a inhaler, it is a no-brainer which one will everybody choose. Mannkind needs to find a good partner to commercialize the product. I am extremely bullish on the stock and I suspect the price to cross $10 once they announce a partner. This is a good time to buy a stock if you have a good risk appetite and expect a huge return on your investment.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:27:22 PM : Underperform Start Price: $5.87 MNKD Score: +5.44

Short. Biopharma. Hardly any revenues. Selling massive amount of stock.

Featured Broker Partners


Advertisement